- Patient/Guest
- Phlebotomist
- Updates
| VMA Catecholamines | - |
|---|
|
Measure VMA and catecholamines in urine |
||
 |
Synonym | See updates |
 |
Test Code | CDBIOPR0030 |
 |
Test Type | Biochemistry |
 |
Pre-Test Condition | See updates |
 |
Report Availability | 3 D(s) |
 |
# Test(s) | Multiple |
| Test details | Sample Report |
|---|---|
| VMA Catecholamines |
|
|
Synonym | See updates | |
|
Test Code | CDBIOPR0030 | |
 |
Test Category | Pheochromocytoma | |
|
Pre-Test Condition | See updates | |
 |
Medical History | See updates | |
|
Report Availability | 3 D(s) | |
 |
Specimen/Sample | Urine; 24 hr; Preserv Cont | |
 |
Stability @21-26 deg. C | 6 Hr(s) | |
 |
Stability @ 2-8 deg. C | 7 D(s) | |
 |
Stability @ Frozen | NA | |
|
# Test(s) | Multiple | |
 |
Processing Method | HPLC | |
| **VMA and Catecholamines 24 Hr Urine****FDA Status**: Standard laboratory procedure under CLIA; no specific FDA approval required.**Other Names**: Vanillylmandelic Acid and Catecholamine Test, Pheochromocytoma Test.**Historical Breakthrough**: Developed in the 1960s to diagnose neuroendocrine tumors, advancing oncology.**Key Purpose and Impact**: Measures VMA and catecholamines in 24-hour urine to diagnose pheochromocytoma or neuroblastoma.**Preparation and Patient History**: 24-hour urine; report hypertension, palpitations, or tumor history.**Consent Requirement**: Standard consent for non-invasive sample collection.**Clinical Value**: Sensitivity ~95%; specificity ~95%; detects tumors in ~90% of cases; guides diagnosis.**References Cited**: Testing.com Oncology Tests 2023; Labcorp VMA/Catecholamine Test 2025; UpToDate Pheochromocytoma 2025 |